Navigation Links
Lupin Announces Litigation Settlement with Schering-Plough Corporation for Desloratadine(R)
Date:12/17/2008

MUMBAI, India, Dec. 17 /PRNewswire/ -- Pharma Major, Lupin Ltd. announced today that it has settled all ongoing Hatch-Waxman litigation relating to Desloratadine tablets, the generic version of Schering-Plough's "Clarinex"(R) tablets.

As per the terms of the settlement, Lupin Ltd. will be licensed under the relevant Desloratadine patents, and free to commercially launch its generic Desloratadine product, on July 1, 2012, or earlier in certain circumstances.

Lupin had earlier filed a Paragraph IV certification to, among others, U.S. Patent Nos. 6,100,274, 7,214,683 and 7,214,684, contesting that these patents were either invalid or had not been infringed upon - resulting in the subsequent litigation by Schering Corp. and Sepracor.

Schering-Plough's Clarinex(R) tablets had U.S. sales of $329 million for the year 2007-MAT June 2008, according to IMS Health.

Commenting on the settlement, Dr. Kamal Sharma, Managing Director, Lupin said - "The settlement with Schering-Plough leaves us strategically poised to further strengthen, consolidate and grow our market position in the U.S. markets. Furthermore, the settlement, recent product approvals and growth in filings across markets are a testament to our increased strengths and focus on Research & Development and the quality of our Intellectual property - a testimony to Lupin's larger goal of developing and delivering quality, cost-effective drugs for everybody."

About Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardiovasculars (prils and statins), Diabetology, Asthma and NSAIDs. The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.

Currently positioned amongst the top six pharmaceutical companies of India, the Company is committed to achieve sustainable earnings and growth for all its stakeholders. For the financial year ended March 2008, the Lupin's Revenues and Profit after Tax were Rs.27,730 million (US$ 694 million) and Rs.4,083 million (US$ 102 million), respectively.

    BSE : 500257    NSE: Lupin    REUTERS: LUPN.BO    BLOOMBERG:LPC IN

    For further information contact: 

    Shamsher Gorawara
    Head - Corporate Communications
    Lupin Limited
    Mobile: +91 9820338555
    shamshergorawara@lupinpharma.com 

    OR

    Archana Pradhan
    Escher PR
    Tel. +91 22 24901327, 24901328
    Mobile: +91 9820330505
    archana@escherpr.com


'/>"/>
SOURCE Lupin Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians
2. Lupin Receives USFDA Approval for Divalproex Sodium Delayed-Release Tablets
3. Lupin Enters Into Marketing Alliance with ASCEND Therapeutics for Suprax(R) 400 mg Tablets in the U.S.
4. Lupin Receives USFDA Approval for Escitalopram Oxalate Tablets
5. Lupin Launches Ramipril Capsules
6. Lupin Receives USFDA Approval for Topiramate Tablets
7. Dynatronics Announces Changes to Board and Launches Operational Improvement Process
8. SantaFe Senior Living Announces Leadership Transition
9. Elsevier announces new partnership between the Journal of Pain and Symptom Management and the AAHPM
10. Finesse Announces TruDO Optical Autoclavable Sensors for Bioprocess Applications
11. Cadence Pharmaceuticals Announces Positive Topline Results of Phase III Clinical Trial of Acetavance in Laparoscopic Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... Charleston, South Carolina (PRWEB) , ... February 19, 2017 , ... ... class of evening undergraduate nursing students, is being led by Amelia Joseph, Ph.D. Joseph ... direct the initial operations of the nursing department in early 2016. After a nation-wide ...
(Date:2/19/2017)... (PRWEB) , ... February 19, 2017 , ... ProBrand Glitch is a set of 30 ... ProBrand Glitch users can easily reveal any logo with a glitch reveal in just a ... control over the style and animation of each preset. Use these presets to add a ...
(Date:2/19/2017)... ... February 19, 2017 , ... ... healthcare, will join forces with Healthwise ® at HIMSS 2017 ... industry leader in evidence-based health education, technology and services, will demonstrate a voice-powered ...
(Date:2/18/2017)... ... February 17, 2017 , ... Focused start-ups, not ... the industry, according to the recent NEJM Catalyst Insights Report on the New ... NEJM Catalyst Insights Council, a qualified group of U.S. executives, clinical leaders, and ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... drvallecillos.com , Beverly Hills plastic surgeon Dr. Glenn Vallecillos experiments ... Dr. Vallecillos says, "Traditionally, plastic surgery has been centered around that idea that ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... 21, 2017 Taiwan Biophotonic Co. (tBPC), a ... vital signs sensing solutions, today announced the CE Marking ... pulse oximeter, the oCare TM Pro 100, which is ... medical devices space.  tBPC,s Wrist Pulse Oximeter, ... simple and reliable method to measure and record heart ...
(Date:2/20/2017)... , Feb. 20, 2017 Provides understanding ... agreements entered into by the worlds leading healthcare ... Description The Global Anemia Partnering Terms ... access to partnering deals and agreements entered into ... - Trends in partnering deals - Top ...
(Date:2/20/2017)... , Feb. 20, 2017  This Report analyzes the worldwide ... Dosage Forms: Injectables, Solid Dosage Forms, and Liquid & Semi-solid Dosage ... Canada , Japan , ... World. Read the full report: http://www.reportlinker.com/p04707109-summary/view-report.html ... Annual estimates ...
Breaking Medicine Technology: